S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:CABA

Cabaletta Bio Competitors

$10.39
-1.17 (-10.12 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.38
Now: $10.39
$11.68
50-Day Range
$10.87
MA: $12.51
$14.33
52-Week Range
$5.51
Now: $10.39
$16.38
Volume209,973 shs
Average Volume116,077 shs
Market Capitalization$249.93 million
P/E RatioN/A
Dividend YieldN/A
Beta1.67

Competitors

Cabaletta Bio (NASDAQ:CABA) Vs. AERI, PASG, TSHA, BDTX, RUBY, and ALGS

Should you be buying CABA stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Cabaletta Bio, including Aerie Pharmaceuticals (AERI), Passage Bio (PASG), Taysha Gene Therapies (TSHA), Black Diamond Therapeutics (BDTX), Rubius Therapeutics (RUBY), and Aligos Therapeutics (ALGS).

Aerie Pharmaceuticals (NASDAQ:AERI) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Earnings and Valuation

This table compares Aerie Pharmaceuticals and Cabaletta Bio's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aerie Pharmaceuticals$69.89 million12.92$-199,580,000.00($3.40)-5.66
Cabaletta BioN/AN/A$-16,940,000.00($4.07)-2.55

Cabaletta Bio has lower revenue, but higher earnings than Aerie Pharmaceuticals. Aerie Pharmaceuticals is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aerie Pharmaceuticals and Cabaletta Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aerie Pharmaceuticals-231.05%-135.57%-37.23%
Cabaletta BioN/A-22.99%-22.38%

Volatility & Risk

Aerie Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500.

Insider & Institutional Ownership

99.9% of Aerie Pharmaceuticals shares are held by institutional investors. Comparatively, 68.0% of Cabaletta Bio shares are held by institutional investors. 9.7% of Aerie Pharmaceuticals shares are held by insiders. Comparatively, 6.5% of Cabaletta Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Aerie Pharmaceuticals and Cabaletta Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aerie Pharmaceuticals11902.73
Cabaletta Bio00303.00

Aerie Pharmaceuticals currently has a consensus price target of $25.50, indicating a potential upside of 32.47%. Cabaletta Bio has a consensus price target of $20.3333, indicating a potential upside of 95.70%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than Aerie Pharmaceuticals.

Summary

Cabaletta Bio beats Aerie Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Cabaletta Bio (NASDAQ:CABA) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

This table compares Cabaletta Bio and Passage Bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cabaletta BioN/AN/A$-16,940,000.00($4.07)-2.55
Passage BioN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and target prices for Cabaletta Bio and Passage Bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cabaletta Bio00303.00
Passage Bio02602.75

Cabaletta Bio currently has a consensus price target of $20.3333, indicating a potential upside of 95.70%. Passage Bio has a consensus price target of $25.5297, indicating a potential upside of 31.39%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Cabaletta Bio is more favorable than Passage Bio.

Insider and Institutional Ownership

68.0% of Cabaletta Bio shares are owned by institutional investors. Comparatively, 67.6% of Passage Bio shares are owned by institutional investors. 6.5% of Cabaletta Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Cabaletta Bio and Passage Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cabaletta BioN/A-22.99%-22.38%
Passage BioN/AN/AN/A

Summary

Cabaletta Bio beats Passage Bio on 4 of the 7 factors compared between the two stocks.

Cabaletta Bio (NASDAQ:CABA) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

This table compares Cabaletta Bio and Taysha Gene Therapies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cabaletta BioN/AN/A$-16,940,000.00($4.07)-2.55
Taysha Gene TherapiesN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and target prices for Cabaletta Bio and Taysha Gene Therapies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cabaletta Bio00303.00
Taysha Gene Therapies00603.00

Cabaletta Bio currently has a consensus price target of $20.3333, indicating a potential upside of 95.70%. Taysha Gene Therapies has a consensus price target of $40.3333, indicating a potential upside of 72.36%. Given Cabaletta Bio's higher probable upside, equities research analysts clearly believe Cabaletta Bio is more favorable than Taysha Gene Therapies.

Insider and Institutional Ownership

68.0% of Cabaletta Bio shares are owned by institutional investors. Comparatively, 42.2% of Taysha Gene Therapies shares are owned by institutional investors. 6.5% of Cabaletta Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Cabaletta Bio and Taysha Gene Therapies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cabaletta BioN/A-22.99%-22.38%
Taysha Gene TherapiesN/AN/AN/A

Cabaletta Bio (NASDAQ:CABA) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

This table compares Cabaletta Bio and Black Diamond Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cabaletta BioN/AN/A$-16,940,000.00($4.07)-2.55
Black Diamond TherapeuticsN/AN/A$-35,260,000.00($16.99)-1.40

Cabaletta Bio is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Cabaletta Bio and Black Diamond Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cabaletta Bio00303.00
Black Diamond Therapeutics00403.00

Cabaletta Bio currently has a consensus price target of $20.3333, indicating a potential upside of 95.70%. Black Diamond Therapeutics has a consensus price target of $51.50, indicating a potential upside of 117.02%. Given Black Diamond Therapeutics' higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Cabaletta Bio.

Insider and Institutional Ownership

68.0% of Cabaletta Bio shares are owned by institutional investors. Comparatively, 65.8% of Black Diamond Therapeutics shares are owned by institutional investors. 6.5% of Cabaletta Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Cabaletta Bio and Black Diamond Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cabaletta BioN/A-22.99%-22.38%
Black Diamond TherapeuticsN/A-22.28%-17.91%

Summary

Black Diamond Therapeutics beats Cabaletta Bio on 5 of the 9 factors compared between the two stocks.

Cabaletta Bio (NASDAQ:CABA) and Rubius Therapeutics (NASDAQ:RUBY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

This table compares Cabaletta Bio and Rubius Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cabaletta BioN/AN/A$-16,940,000.00($4.07)-2.55
Rubius TherapeuticsN/AN/A$-163,460,000.00($2.08)-5.00

Rubius Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Cabaletta Bio and Rubius Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cabaletta Bio00303.00
Rubius Therapeutics03202.40

Cabaletta Bio currently has a consensus price target of $20.3333, indicating a potential upside of 95.70%. Rubius Therapeutics has a consensus price target of $13.25, indicating a potential upside of 27.40%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Cabaletta Bio is more favorable than Rubius Therapeutics.

Insider and Institutional Ownership

68.0% of Cabaletta Bio shares are owned by institutional investors. Comparatively, 93.7% of Rubius Therapeutics shares are owned by institutional investors. 6.5% of Cabaletta Bio shares are owned by company insiders. Comparatively, 58.4% of Rubius Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Cabaletta Bio and Rubius Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cabaletta BioN/A-22.99%-22.38%
Rubius TherapeuticsN/A-77.33%-49.05%

Risk and Volatility

Cabaletta Bio has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Rubius Therapeutics has a beta of 2.37, suggesting that its share price is 137% more volatile than the S&P 500.

Summary

Cabaletta Bio beats Rubius Therapeutics on 6 of the 11 factors compared between the two stocks.

Cabaletta Bio (NASDAQ:CABA) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

This table compares Cabaletta Bio and Aligos Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cabaletta BioN/AN/A$-16,940,000.00($4.07)-2.55
Aligos TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and target prices for Cabaletta Bio and Aligos Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cabaletta Bio00303.00
Aligos Therapeutics00403.00

Cabaletta Bio currently has a consensus price target of $20.3333, indicating a potential upside of 95.70%. Aligos Therapeutics has a consensus price target of $30.50, indicating a potential upside of 41.60%. Given Cabaletta Bio's higher probable upside, equities research analysts clearly believe Cabaletta Bio is more favorable than Aligos Therapeutics.

Insider and Institutional Ownership

68.0% of Cabaletta Bio shares are owned by institutional investors. 6.5% of Cabaletta Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Cabaletta Bio and Aligos Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cabaletta BioN/A-22.99%-22.38%
Aligos TherapeuticsN/AN/AN/A


Cabaletta Bio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25-1.6%$903.15 million$69.89 million-4.59
Passage Bio logo
PASG
Passage Bio
1.9$19.43-2.7%$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40-7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73-8.0%$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40-10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83-12.0%$533.77 millionN/A-4.29Upcoming Earnings
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.7$20.44-2.7%$529.60 millionN/A-5.89
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$11.45-6.7%$519.76 million$147.87 million-3.80Analyst Upgrade
Gap Up
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.59-1.8%$513.21 million$4.36 million-4.75Upcoming Earnings
Increase in Short Interest
HARP
Harpoon Therapeutics
1.5$19.14-4.3%$485.77 million$5.78 million-8.99Upcoming Earnings
News Coverage
Gap Up
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.43-2.8%$476.93 millionN/A0.00Upcoming Earnings
Opthea logo
OPT
Opthea
1.5$9.35-7.0%$394.65 millionN/A0.00Decrease in Short Interest
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$19.75-0.0%$384.69 million$340,000.00-6.98
AVROBIO logo
AVRO
AVROBIO
1.7$10.54-4.6%$384.19 millionN/A-3.19
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.5$13.50-7.9%$349.93 millionN/A0.00High Trading Volume
Gap Down
Codiak BioSciences logo
CDAK
Codiak BioSciences
1.9$15.82-2.5%$347.25 millionN/A0.00Analyst Upgrade
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$9.18-10.1%$340.14 million$250,000.00-3.28Analyst Revision
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.30-2.1%$339.62 million$96.12 million-12.65Upcoming Earnings
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$3.71-6.2%$329.60 millionN/A-5.80High Trading Volume
Decrease in Short Interest
News Coverage
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$13.25-7.4%$329.00 millionN/A0.00Upcoming Earnings
Increase in Short Interest
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$6.20-3.4%$323.95 million$2.91 million-2.16Increase in Short Interest
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$1.81-11.0%$313.91 million$8.15 million-1.45Decrease in Short Interest
Surface Oncology logo
SURF
Surface Oncology
1.3$7.53-12.5%$306.30 million$15.36 million-11.41Upcoming Earnings
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.6$9.24-8.3%$300.60 millionN/A-3.80Upcoming Earnings
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
1.3$13.50-7.9%$290.94 millionN/A0.00
PDL BioPharma logo
PDLI
PDL BioPharma
1.1$2.47-0.0%$282.14 million$54.76 million-2.19Upcoming Earnings
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.5$2.18-9.6%$270.20 million$4.13 million-4.84News Coverage
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$7.84-6.8%$249.20 millionN/A-4.90Analyst Report
News Coverage
Gap Down
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$5.06-7.1%$215.85 million$2.45 million-2.38Gap Up
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$2.23-5.4%$210.84 million$29.35 million-2.59Upcoming Earnings
News Coverage
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$5.58-0.7%$210.11 million$104.39 million-3.40
Axcella Health logo
AXLA
Axcella Health
1.6$5.51-3.1%$206.85 millionN/A-2.56
INmune Bio logo
INMB
INmune Bio
1.5$15.37-22.5%$206.70 millionN/A-15.85Earnings Announcement
News Coverage
Gamida Cell logo
GMDA
Gamida Cell
1.4$8.43-6.3%$204.18 millionN/A-5.90Upcoming Earnings
Increase in Short Interest
Gap Up
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.